Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 12, Issue 6, Pages 319-334
Publisher
Springer Nature
Online
2015-03-31
DOI
10.1038/nrclinonc.2015.53
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- O-0003 * NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY
- (2014) D. Von Hoff et al. ANNALS OF ONCOLOGY
- pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
- (2014) Steffen Ormanns et al. BMC CANCER
- Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
- (2014) E Van Cutsem et al. BRITISH JOURNAL OF CANCER
- Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
- (2014) Berna C. Özdemir et al. CANCER CELL
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Testicular Cancer and Platinum: A Double-Edged Sword
- (2014) Aine O'Reilly et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
- (2014) Lee M. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel
- (2014) D. B. Johnson et al. ONCOLOGIST
- Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma
- (2014) B. M. Wolpin et al. ONCOLOGIST
- Evidence for the Importance of Personalized Molecular Profiling in Pancreatic Cancer
- (2014) Loukia N. Lili et al. PANCREAS
- Stromal response to Hedgehog signaling restrains pancreatic cancer progression
- (2014) J. J. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
- (2014) E. R. Lutz et al. Cancer Immunology Research
- Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial
- (2013) F. C. Bidard et al. ANNALS OF ONCOLOGY
- Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
- (2013) R Alvarez et al. BRITISH JOURNAL OF CANCER
- Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
- (2013) A. Quintas-Cardama et al. CLINICAL CANCER RESEARCH
- Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
- (2013) C. C. S. Chini et al. CLINICAL CANCER RESEARCH
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
- (2013) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
- (2013) Philippe Rougier et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial
- (2013) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
- (2013) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
- (2013) Hideki Ueno et al. JOURNAL OF CLINICAL ONCOLOGY
- Is It Better to Transfer Long-Term Cancer Survivors to General Practitioners or Develop Clinics for Long-Term Survivors Within the Cancer Centers?
- (2013) Umberto Tirelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
- (2013) William Greenhalf et al. JNCI-Journal of the National Cancer Institute
- Improvement of surgical results for pancreatic cancer
- (2013) Werner Hartwig et al. LANCET ONCOLOGY
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
- (2013) Somnath Mukherjee et al. LANCET ONCOLOGY
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
- (2013) Gunther Zimmermann et al. NATURE
- US National Cancer Institute's new Ras project targets an old foe
- (2013) Helen Thompson NATURE MEDICINE
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- The immune network in pancreatic cancer development and progression
- (2013) S M Wörmann et al. ONCOGENE
- FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience
- (2013) J. E. Faris et al. ONCOLOGIST
- Mutant KRAS is a druggable target for pancreatic cancer
- (2013) E. Zorde Khvalevsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neoadjuvant Therapy and Vascular Resection During Pancreaticoduodenectomy: Shifting the Survival Curve for Patients with Locally Advanced Pancreatic Cancer
- (2013) Irene Epelboym et al. WORLD JOURNAL OF SURGERY
- Clinical and molecular characterization of HER2 amplified-pancreatic cancer
- (2013) Angela Chou et al. Genome Medicine
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
- (2012) A. Gonçalves et al. ANNALS OF ONCOLOGY
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
- (2012) J Harder et al. BRITISH JOURNAL OF CANCER
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
- (2012) Matthew H. G. Katz et al. CANCER
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
- (2012) Carolina Navas et al. CANCER CELL
- FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
- (2012) Alberto Zaniboni et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- EMT and Dissemination Precede Pancreatic Tumor Formation
- (2012) Andrew D. Rhim et al. CELL
- Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply
- (2012) A. Le et al. CLINICAL CANCER RESEARCH
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
- (2012) Michael A Jacobetz et al. GUT
- Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer
- (2012) Daniel Laheru et al. INVESTIGATIONAL NEW DRUGS
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
- (2012) Sophie Gourgou-Bourgade et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity
- (2012) Krishna S. Gunturu et al. MEDICAL ONCOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies
- (2011) Angelo Andriulli et al. ANNALS OF SURGICAL ONCOLOGY
- STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis
- (2011) R. B. Corcoran et al. CANCER RESEARCH
- Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer
- (2011) I. Garrido-Laguna et al. CLINICAL CANCER RESEARCH
- Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
- (2011) J. D. Sun et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
- (2011) J. Godin-Ethier et al. CLINICAL CANCER RESEARCH
- A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
- (2011) D. T. Le et al. CLINICAL CANCER RESEARCH
- Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
- (2011) Hideaki Ijichi et al. JOURNAL OF CLINICAL INVESTIGATION
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
- (2011) Patrick J. Loehrer et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
- (2011) Francesca De Bacco et al. JNCI-Journal of the National Cancer Institute
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
- (2011) S. T. Kim et al. MOLECULAR CANCER THERAPEUTICS
- The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins
- (2011) Anchal Chandra et al. NATURE CELL BIOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials
- (2011) M. Mura Assifi et al. SURGERY
- Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
- (2010) I Garrido-Laguna et al. BRITISH JOURNAL OF CANCER
- Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer
- (2010) Gilda da Cunha Santos et al. CANCER
- Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
- (2010) M. J. Seltzer et al. CANCER RESEARCH
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
- (2010) Giuseppe Colucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome
- (2010) Heinz-Josef Klümpen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma
- (2010) Zeshaan A. Rasheed et al. JNCI-Journal of the National Cancer Institute
- Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
- (2010) M. C. Villarroel et al. MOLECULAR CANCER THERAPEUTICS
- A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model
- (2010) N. V. Rajeshkumar et al. MOLECULAR CANCER THERAPEUTICS
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
- (2010) Sonja Gillen et al. PLOS MEDICINE
- Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials
- (2009) J P Neoptolemos et al. BRITISH JOURNAL OF CANCER
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
- (2009) Christine A. Iacobuzio-Donahue et al. JOURNAL OF CLINICAL ONCOLOGY
- A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
- (2009) A. Jimeno et al. MOLECULAR CANCER THERAPEUTICS
- Variation in Hospital Mortality Associated with Inpatient Surgery
- (2009) Amir A. Ghaferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
- (2009) Charles M. Rudin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- (2009) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
- (2008) B. Chauffert et al. ANNALS OF ONCOLOGY
- Most Pancreatic Cancer Resections are R1 Resections
- (2008) Irene Esposito et al. ANNALS OF SURGICAL ONCOLOGY
- Influence of Resection Margins and Treatment on Survival in Patients With Pancreatic Cancer
- (2008) Giovanni Butturini ARCHIVES OF SURGERY
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
- (2008) Volker Heinemann et al. BMC CANCER
- Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression
- (2008) R. F. Hwang et al. CANCER RESEARCH
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- The Activated Stroma Index Is a Novel and Independent Prognostic Marker in Pancreatic Ductal Adenocarcinoma
- (2008) Mert Erkan et al. Clinical Gastroenterology and Hepatology
- Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Gauri R. Varadhachary et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital
- (2008) Joseph M. Herman et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Douglas B. Evans et al. JOURNAL OF CLINICAL ONCOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection
- (2008) Agnes Witkiewicz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- A paracrine requirement for hedgehog signalling in cancer
- (2008) Robert L. Yauch et al. NATURE
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now